KPV
CosmeticAnti-inflammatory MSH fragment / researchExperimental
C-terminal α-MSH tripeptide with anti-inflammatory activity in gut and skin models without strong melanotropic tanning. Not FDA-approved.
For research use only.
Key Facts
- CAS
- 67727-97-3
- Molecular Weight (MW)
- 342.44 g/mol
- Half-life
- Short; topical and research injectable use
- Unit
- mcg
- Administration Route
- Subcutaneous
- Frequency
- 1–2× daily (short-term)
- Last updated
- 8/23/2026
- Targets
- NF-κB pathwayMC1R (weak)
Overview
C-terminal α-MSH tripeptide with anti-inflammatory activity in gut and skin models without strong melanotropic tanning. Not FDA-approved.
Protocol
- Dosage Range
- 100–500 mcg per dose
- Frequency
- 1–2× daily (short-term)
- Cycle
- Short courses as needed
- Administration Route
- Subcutaneous
- Reconstitution Guide
- —
Science
Mechanism of Action
Inhibits NF-κB–mediated cytokine production in epithelial and immune cells; retains anti-inflammatory signaling of α-MSH with less MC1R pigmentation.
Targets
NF-κB pathwayMC1R (weak)
Studies
- KPV anti-inflammatory tripeptide— Journal/year not available
Benefits
Gut and skin inflammation models
Potential Side Effects
- Mild irritation
- Limited human data
References
- PMID 12975471External link · Year —